11/24/2004

GlaxoSmithKline's R&D chairman opposes creation of a separate agency to monitor the safety of FDA-approved drugs. Tachi Yamada said splitting the process is a hazardous idea and drugs should be reviewed in their totality. Separately, a Journal and Constitution editorial supports the proposal to create an agency independent of the FDA because the agency no longer has the trust of the public.

Related Summaries